For people with vitiligo and their caregivers
What this page helps you do
Learn what off-label tacrolimus use means and what results are uncertain. Review its strongest warning and what to ask if light therapy is also planned.
- Your task
- Understand the current definition, evidence boundary, practical burden, and questions that affect fit.
- The clinician boundary
- Diagnosis, assessment of activity and body sites, prescribing, monitoring, and personalized treatment decisions belong to a qualified clinician.
Why was I offered tacrolimus if it is not approved for vitiligo?
In the United States, tacrolimus ointment is approved for specified atopic dermatitis use, not vitiligo, so using it for vitiligo is off-label. Clinicians may still offer an off-label medicine when they judge the broader evidence relevant. Protopic is a brand name; the current label for the exact product you receive still matters. Evidence Evidence Evidence
Why this matters
Tacrolimus is a topical calcineurin inhibitor that affects immune signaling in skin. Vitiligo guidelines discuss it as one topical option, including when a clinician is considering alternatives to corticosteroids.
What are realistic expectations for my patches?
Research on topical calcineurin inhibitors, including tacrolimus, reports repigmentation in some people with vitiligo. The studies vary, and personal response, extent of change, and durability remain individual. Evidence Evidence Evidence
Why this matters
The systematic review combined studies with different participants, body sites, treatment contexts, and definitions of success. Guidelines use that broader evidence to support discussing an option—not to claim every patch responds the same way.
What should I know about the boxed warning and skin reactions?
The US label for tacrolimus ointment carries the FDA’s strongest safety alert. This is called a “boxed warning.” It notes rare cancer reports but says the medicine has not been proven to cause them. It also warns against continuous long-term use. Burning, stinging, soreness, or itching can occur where you apply it. Evidence
Why this matters
The boxed warning and Medication Guide should be part of your decision. The phrase “steroid-free” must not hide them. Local discomfort can happen. Ask your care team whether a reaction is expected or needs attention.
What if I am also using or considering phototherapy?
Tell both the prescriber and phototherapy team. The tacrolimus label tells patients to minimize or avoid natural and artificial sunlight, including ultraviolet treatment, while vitiligo guidelines discuss selected clinician-supervised combinations. That conflict needs an explicit, coordinated answer; it is not permission to combine them on your own. Evidence Evidence Evidence
Why this matters
The product label sets approved warnings for tacrolimus, while guidelines assess a broader evidence base that includes off-label practice. A qualified prescriber and phototherapy team need to reconcile both for you and the exact products involved.
Questions that can change the next decision
- For your clinicianWho is coordinating the tacrolimus and phototherapy instructions?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- For your clinicianWho resolves conflicts in my written instructions?Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence and update context
This optional layer shows the evidence boundary reviewed for this page as of 2026-08-03.
- What this evidence supports
- Tacrolimus is a topical calcineurin inhibitor that affects immune signaling in skin. Vitiligo guidelines discuss it as one topical option, including when a clinician is considering alternatives to corticosteroids.
- What it does not establish
- Off-label use does not create a regulator-reviewed vitiligo indication, and guideline inclusion does not mean tacrolimus fits you. Your age, body area, immune status, other medicines, and the current product label all matter.
Applicability check
Who was studied?
These fields show what the cited evidence reports about the people and body sites behind outcome or safety claims. “Not reported” means the reviewed source omitted the field; “Pending exact source review” means SteadySkin has not made that determination yet.
Research on topical calcineurin inhibitors, including tacrolimus, reports repigmentation in some people with vitiligo. The studies vary, and personal response, extent of change, and durability remain individual.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: This is explicitly gated as a group-level outcome claim, but exact population extraction is still pending. It cannot publish or support an individual prediction until that review is complete.
The US label for tacrolimus ointment carries the FDA’s strongest safety alert. This is called a “boxed warning.” It notes rare cancer reports but says the medicine has not been proven to cause them. It also warns against continuous long-term use. Burning, stinging, soreness, or itching can occur where you apply it.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: This is explicitly gated as a safety claim, but exact population extraction is still pending. It cannot publish or support an estimate of individual risk until that review is complete.
Tell both the prescriber and phototherapy team. The tacrolimus label tells patients to minimize or avoid natural and artificial sunlight, including ultraviolet treatment, while vitiligo guidelines discuss selected clinician-supervised combinations. That conflict needs an explicit, coordinated answer; it is not permission to combine them on your own.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: This is explicitly gated as a safety claim, but exact population extraction is still pending. It cannot publish or support an estimate of individual risk until that review is complete.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- DailyMed, U.S. National Library of MedicineRegulatory / guideline · not independentRelevant relationship disclosed
- Published
- 2026-01-28
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
Why the independence label says this: The National Library of Medicine hosts DailyMed. The product company submits the label to FDA, so it is authoritative for product labeling but not independent efficacy evidence.
What this source supports
It establishes the US atopic-dermatitis indication, boxed warning, local effects, long-term-use precaution, and ultraviolet instructions for this product.
What it does not support
It does not approve tacrolimus for vitiligo, establish vitiligo efficacy, or resolve off-label guideline discussion of supervised combinations.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- JAMA Dermatology (Lee JH, et al.)Clinical research · independentIndependent source
- Published
- 2019-05-29
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports pooled group-level repigmentation outcomes for topical calcineurin inhibitors alone and with phototherapy, including variation by body area.
What it does not support
Considerable study heterogeneity limits product-specific and individual inference, and the review does not override current product labels or prove one medicine superior.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- Journal of the European Academy of Dermatology and VenereologyRegulatory / guideline · not independentRelevant relationship disclosed
- Published
- 2023-09-25
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- British Journal of Dermatology (Eleftheriadou V, et al.)Regulatory / guideline · independentIndependent source
- Published
- 2022-01-01
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.